Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Krystal Biotech (KRYS) EPS (Basic) (2021 - 2025)

Krystal Biotech's EPS (Basic) history spans 5 years, with the latest figure at $1.77 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 11.32% year-over-year to $1.77; the TTM value through Dec 2025 reached $7.08, up 127.65%, while the annual FY2025 figure was $7.08, 126.92% up from the prior year.
  • EPS (Basic) for Q4 2025 was $1.77 at Krystal Biotech, down from $2.74 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $3.09 in Q3 2023 and bottomed at -$1.99 in Q1 2022.
  • The 5-year median for EPS (Basic) is -$0.34 (2021), against an average of $0.1.
  • The largest annual shift saw EPS (Basic) plummeted 168.92% in 2022 before it surged 4033.33% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.95 in 2021, then crashed by 31.58% to -$1.25 in 2022, then surged by 125.6% to $0.32 in 2023, then soared by 396.88% to $1.59 in 2024, then rose by 11.32% to $1.77 in 2025.
  • Per Business Quant, the three most recent readings for KRYS's EPS (Basic) are $1.77 (Q4 2025), $2.74 (Q3 2025), and $1.33 (Q2 2025).